<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-111 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-111</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-111</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <p><strong>Paper ID:</strong> paper-8d1ae1b50354fb5c4d11a20cf33dfaf7981be0e9</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/8d1ae1b50354fb5c4d11a20cf33dfaf7981be0e9" target="_blank">High-resolution genomic profiles of human lung cancer.</a></p>
                <p><strong>Paper Venue:</strong> Proceedings of the National Academy of Sciences of the United States of America</p>
                <p><strong>Paper TL;DR:</strong> An integrated high-resolution survey of regional amplifications and deletions, coupled with gene-expression profiling of non-small-cell lung cancer subtypes, identified 93 focal copy-number alterations, of which 21 span <0.5 megabases and contain a median of five genes.</p>
                <p><strong>Cost:</strong> 0.018</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e111.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e111.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>WHSC1L1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A SET-domain containing histone lysine methyltransferase family member located in a focal 8p12-p11.2 amplicon; proposed by this paper as the likely target oncogene of that amplification in non-small-cell lung cancer (including lung adenocarcinoma).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>High-resolution aCGH and expression profiling on a cohort of 44 NSCLC samples (18 primary lung adenocarcinomas and 26 primary squamous carcinomas; >70% tumor cellularity) plus a panel of NSCLC cell lines; primary tumors were from Cooperative Human Tissue Network and Brigham and Women's Hospital tissue bank.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>18</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>High-resolution array-CGH (oligonucleotide arrays median resolution ~54.8 kb; cDNA arrays median resolution ~72.7 kb), expression profiling (Affymetrix/Agilent platforms), QPCR (real-time), FISH (interphase and metaphase), RT-QPCR, siRNA knockdown, soft-agar colony assays; QPCR and FISH used to delimit amplicon boundaries.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Focal high-level copy-number amplification of 8p12-p11.2 targeting WHSC1L1 (minimal common region ~0.14 Mb containing WHSC1L1 and LETM2); WHSC1L1 shows copy-number-driven overexpression and functional dependency in an amplified cell line.</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>copy-number amplification</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>WHSC1L1 (SET2-family histone lysine methyltransferase) — implicates chromatin/epigenetic regulatory mechanisms rather than canonical RTK/RAS/RAF signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Amplicon present in six primary tumors and two cell lines across the NSCLC dataset (paper does not give a breakdown exclusively for the 18 adenocarcinomas); minimal common region defined using at least two informative primary tumors (PT3, PT5).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Not reported for WHSC1L1 (no analysis of mutual exclusivity with EGFR/KRAS/other drivers presented).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Focal, high-amplitude amplification localized by QPCR and FISH to a 0.14 Mb MCR; consistent copy-number-driven overexpression in expression arrays and RT-QPCR; cross-tumor recurrence (also observed in pancreatic datasets and reported in other cancers); literature links (translocation in AML, amplification in breast cancer); functional evidence from siRNA dependency.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>siRNA pool knockdown in NCI-H1703 (cell line with 8p amplification) produced >70% mRNA knockdown and ~50% reduction in soft-agar colony formation; no effect in non-amplified cell line NCI-H1395. QPCR, FISH validated amplification boundaries.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Paper does not test drugs; mechanistic class (histone methyltransferase) suggests potential targeting by epigenetic/enzymatic inhibitors, but no therapeutic data are provided in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>WHSC1L1 identified by integrated DNA-RNA analysis as copy-number-driven expression outlier; no specific global transcriptomic signature for WHSC1L1-amplified (or driver-negative) adenocarcinomas is reported beyond overexpression of the gene in amplified samples.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not reported in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Amplicon observed among NSCLC samples; paper does not provide a clear split of WHSC1L1 amplification frequency limited to adenocarcinoma versus squamous beyond using primary tumors PT3/PT5 to delimit MCR; cross-tumor recurrence (also in pancreatic ductal adenocarcinoma and reported in breast cancer).</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Small cohort size and limited breakdown by histology for this specific amplicon; amplification may be subclonal in some tumors; further functional validation and larger cohort analyses required; paper also notes FGFR1 (previously implicated in larger 8p amplicons) is excluded here, illustrating the importance of high-resolution mapping to avoid bystander misassignment.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Amplification -> increased WHSC1L1 expression -> altered histone methylation / chromatin states -> transcriptional/epigenetic reprogramming that promotes oncogenic programs (epigenetic oncogene activity).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'High-resolution genomic profiles of human lung cancer.', 'publication_date_yy_mm': '2005-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e111.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TPX2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Targeting protein for Xklp2 (TPX2)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A microtubule-associated protein required for targeting Aurora A kinase to the mitotic spindle; identified in a focal 20q11.2 amplicon and proposed as a candidate oncogene in NSCLC (including at least one primary adenocarcinoma) with copy-number-driven overexpression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Same NSCLC cohort as above: 44 NSCLC samples (18 primary adenocarcinomas, 26 primary squamous carcinomas) and NSCLC cell lines; amplicon detection integrated with expression profiling.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>18</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>High-resolution array-CGH, expression microarrays (Affymetrix/Agilent), delimitation of MCR across samples; no dedicated functional knockdown experiments for TPX2 reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Focal amplification at 20q11.2 (MCR ~220 kb) encompassing ID1, COX4I2, BCL2L1, TPX2, and MYLK2; TPX2 shows strong copy-number-driven overexpression in most amplified cell lines / tumors tested and is nominated as the likely target.</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>copy-number amplification / expression outlier</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>TPX2 — mitotic spindle assembly and Aurora A kinase targeting; implicates cell cycle/mitotic progression pathway (potentially leading to chromosomal instability), not RTK/RAS/RAF signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Amplicon detected in one primary lung adenocarcinoma, one adenosquamous cell line, one SCC cell line, and two adenocarcinoma cell lines (paper gives these counts explicitly).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Not reported; paper notes high expression correlation between TPX2 and Aurora A and many mitotic genes (Bub1, CDC20, Aurora B) but does not report exclusivity with canonical RTK/RAS drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Focal amplification with copy-number-driven overexpression across samples; recurrence across tumor types (also observed in pancreatic ductal adenocarcinoma); strong expression correlation with mitotic machinery genes and literature evidence of overexpression in lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No direct functional knockdown/overexpression experiments for TPX2 reported in this paper; functional inference based on expression correlation with mitotic genes and prior literature (cited) showing overexpression in lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Paper suggests biological link to Aurora A pathway (TPX2 required for Aurora A targeting), implying potential relevance of Aurora kinase pathway inhibitors, but no therapeutic experiments or responses are reported.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>TPX2 expression strongly correlates with Aurora A and other spindle/mitotic genes (high Pearson r values cited), suggesting an expression signature of mitotic/spindle activation in TPX2-amplified samples.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Amplicon observed in a mix of sample types; one primary adenocarcinoma contained the 20q11.2 amplicon; no further clinical associations (stage, smoking, prognosis) are described.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Limited number of primary samples with this amplicon (only one primary AC reported), lack of direct functional validation in this study, and possibility that correlated mitotic-gene expression reflects proliferative index rather than direct oncogenic driver effect; further work required.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Amplification -> increased TPX2 expression -> enhanced recruitment/activation of Aurora A at spindle -> dysregulated mitosis/chromosomal instability and accelerated cell-cycle progression -> contributes to tumorigenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'High-resolution genomic profiles of human lung cancer.', 'publication_date_yy_mm': '2005-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e111.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BCL2L1 (BCL-xL)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BCL2-like 1 (BCL2L1, also known as BCL-xL)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An anti-apoptotic BCL2 family member found within a focal 20q11.2 amplicon in some NSCLC samples; shows modest copy-number-driven overexpression and is a plausible oncogene in amplified tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Same NSCLC cohort: 44 NSCLC samples (18 adenocarcinomas, 26 squamous) and NSCLC cell lines; integrated aCGH and expression profiling used to prioritize genes in amplicons.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>18</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>High-resolution array-CGH, expression microarrays, copy-number-driven expression analysis; no functional perturbation experiments for BCL2L1 reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Copy-number amplification of the 20q11.2 region that includes BCL2L1, with modestly elevated expression of BCL2L1 in amplified samples.</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>copy-number amplification / expression outlier</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>BCL2L1 — anti-apoptotic signaling (intrinsic apoptosis pathway), potentially promoting cell survival independent of RTK/RAS/RAF signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Amplicon detected in one primary lung adenocarcinoma and several cell lines (paper reports detection in one primary lung AC, one adenosquamous cell line, one SCC cell line and two AC cell lines for the 20q11.2 region; BCL2L1 exhibited modest expression increases among these).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Localization to a focal amplicon, modest copy-number-driven expression increase, prior literature implicating BCL2L1 as an oncogene in other cancers (e.g., pancreatic), but limited direct evidence in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>None reported in this paper for BCL2L1 (no knockdown or drug perturbation shown here).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>By implication, tumors with BCL2L1 amplification might be sensitive to inhibitors of BCL-xL or BH3-mimetics, but no therapeutic experiments or responses are provided in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>BCL2L1 showed modest overexpression in amplified samples, but TPX2 (in same amplicon) had stronger copy-number-driven expression; no distinct omics signature for BCL2L1-amplified adenocarcinomas reported.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Detected across sample types in the NSCLC cohort; specific clinical associations not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Modest expression increase raises uncertainty whether BCL2L1 is the key driver of the amplicon (TPX2 showed stronger evidence); further functional testing required to establish causality.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Amplification -> increased BCL2L1 expression -> enhanced anti-apoptotic signaling -> increased tumor cell survival and contribution to oncogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'High-resolution genomic profiles of human lung cancer.', 'publication_date_yy_mm': '2005-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e111.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FGFR1 (excluded)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Fibroblast growth factor receptor 1 (FGFR1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A receptor tyrosine kinase located near the telomeric boundary of a broader 8p amplicon historically implicated in cancers; in this paper FGFR1 is tested and excluded as the target oncogene of the focal 8p12-p11.2 amplicon in the examined lung cancer samples.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Same NSCLC cohort of 44 samples (18 adenocarcinomas, 26 squamous) and cell lines; high-resolution mapping and expression used to define amplicon boundaries.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>18</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Array-CGH (high resolution), QPCR boundary mapping, interphase/metaphase FISH, RT-QPCR, targeted exon sequencing of juxtamembrane and kinase domains, siRNA knockdown and soft-agar colony assays.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>FGFR1 lies within a larger 8p amplification region in other cancers, but in the focal 8p12-p11.2 MCR defined here FGFR1 was found outside the MCR and not amplified or overexpressed in the informative tumors; functional knockdown of FGFR1 had no effect on colony formation in the amplified cell line tested.</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>assessed and experimentally excluded (not a driver in the focal MCR in these samples)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>FGFR1 would implicate RTK/MAPK signaling if it were the target, but the paper's data argue against FGFR1 involvement in these focal 8p amplifications in lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>FGFR1 is not amplified in the focal 8p12 MCR samples defined here; QPCR and FISH show two copies in key primary tumor PT3 and others used to define MCR.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Not specifically reported; paper documents absence of FGFR1 amplification in the focal 8p MCR samples.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>High-resolution QPCR and FISH mapping showing FGFR1 lies outside the 0.14 Mb MCR and is not amplified; sequencing of juxtamembrane and kinase exons revealed no mutations; siRNA-mediated depletion of FGFR1 produced no phenotype in soft-agar assays.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>siRNA-mediated knockdown of FGFR1 in NCI-H1703 (the cell line with 8p amplification where FGFR1 was evaluated) produced near-complete depletion of FGFR1 mRNA/protein but had no impact on soft-agar colony formation; sequencing of FGFR1 kinase/juxtamembrane exons found no mutations (data not shown in detail).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Data argue against pursuing FGFR1-targeted therapy for tumors with the small 8p12-p11.2 MCR in this cohort; no drug-response data presented.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>FGFR1 expression consistent with placement outside the focal MCR (no copy-number-driven overexpression in the informative samples).</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>FGFR1 is historically implicated in larger 8p amplifications across tumor types, but in this NSCLC cohort it was excluded from the focal amplification targeting WHSC1L1; no specific clinical correlations are provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>FGFR1 may be a target in other tumors with broader 8p amplifications, and lower-resolution studies that implicated FGFR1 may have been unable to resolve MCR boundaries; highlights importance of high-resolution mapping to distinguish true targets from bystanders.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Not applicable here — FGFR1 is explicitly excluded as the driver of the focal 8p12-p11.2 amplicon in the analyzed lung cancer samples.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'High-resolution genomic profiles of human lung cancer.', 'publication_date_yy_mm': '2005-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Simon, R., Richter, J., Wagner, U., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knonagel, H., et al. (2001) Cancer Res. 61, 4514-4519. <em>(Rating: 2)</em></li>
                <li>Angrand, P. O., Apiou, F., Stewart, A. F., Dutrillaux, B., Losson, R. & Chambon, P. (2001) Genomics 74, 79-88. <em>(Rating: 2)</em></li>
                <li>Rosati, R., La Starza, R., Veronese, A., Aventin, A., Schwienbacher, C., Vallespi, T., Negrini, M., Martelli, M. F. & Mecucci, C. (2002) Blood 99, 3857-3864. <em>(Rating: 2)</em></li>
                <li>Manda, R., Kohno, T., Matsuno, Y., Takenoshita, S., Kuwano, H. & Yokota, J. (1999) Genomics 61, 5-14. <em>(Rating: 2)</em></li>
                <li>Ray, M. E., Yang, Z. Q., Albertson, D., Kleer, C. G., Washburn, J. G., Macoska, J. A. & Ethier, S. P. (2004) Cancer Res. 64, 40-47. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>